Gilead Sciences, Inc. with ticker code (GILD) have now 27 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $125.00 and $73.00 suggesting an average Analsyt target price of $97.85. Now with the previous closing price of $93.39 this would indicate that there is a potential upside of 4.8%. There is a 50 day moving average of $89.02 and the 200 day moving average is $76.03. The company has a market cap of 114.82B. The stock price is currently at: $92.13 USD
The potential market cap would be $120,300,857,730 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 1023.67, revenue per share of $22.70 and a 11.96% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
